Abstract
The omega-conopeptide, ziconotide, is an N-type calcium-channel blocker that has been shown to produce antinociception in animals using formalin and hot-plate tests. Initial reports of intrathecal administration of ziconotide in cancer and AIDS patients whose pain was unrelieved with opioids demonstrated analgesic efficacy. Although adverse effects were reported, these appeared to be easily managed through dose reduction or symptomatic treatment. This clinical report describes the experiences of three patients with serious adverse effects associated with intrathecal ziconotide.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Ataxia / chemically induced
-
Back Pain / complications
-
Calcium Channel Blockers / administration & dosage
-
Calcium Channel Blockers / adverse effects*
-
Calcium Channel Blockers / therapeutic use
-
Confusion / chemically induced
-
Confusion / psychology
-
Humans
-
Hypotension, Orthostatic / chemically induced
-
Injections, Spinal
-
Male
-
Middle Aged
-
Multiple Sclerosis / complications
-
Nystagmus, Pathologic / chemically induced
-
Pain / drug therapy
-
Pain / etiology
-
Urinary Bladder Neoplasms / complications
-
omega-Conotoxins / administration & dosage
-
omega-Conotoxins / adverse effects*
-
omega-Conotoxins / therapeutic use
Substances
-
Calcium Channel Blockers
-
omega-Conotoxins
-
ziconotide